Since high pCR is suggestive of greater recurrence-free survival, this data suggests that platinum-based agents may be an effective neoadjuvant chemotherapeutic option for women with BRCA-1 positive breast cancer [65]. This evidence concerns the gene BRCA1 and breast carcinoma.